Malignant Hyperthermia: Difference between revisions
No edit summary |
No edit summary |
||
Line 38: | Line 38: | ||
[https://pubmed.ncbi.nlm.nih.gov/38329334/ Improving Dantrolene Mobilization in Regions with Limited Availability] | [https://pubmed.ncbi.nlm.nih.gov/38329334/ Improving Dantrolene Mobilization in Regions with Limited Availability] | ||
[https://pubs.asahq.org/monitor/article/88/7/1/141615/The-Story-Behind-the-MH-Hotline The Story Behind the MH Hotline] |
Revision as of 19:54, 11 July 2024
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
History of Malignant Hyperthermia
See also Malignant Hypertgermia Association of the United States
Malignant hyperthermia 2020 Guideline from the Association of Anaesthetists
Malignant Hyperthermia Resource Kit
Twitter Thread: Building an MH Cart
New device simplifies workstation preparation for malignant hyperthermia-susceptible patients
What is malignant hyperthermia susceptibility?
Real Evidence and Misconceptions about Malignant Hyperthermia in Children: A Narrative Review
Improving Dantrolene Mobilization in Regions with Limited Availability